| Overview |
| bsm-30074m-fitc-100t |
| human CD14/FITC |
| FCM |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Monoclonal |
| 14F4 |
| IgG1/Kappa |
| n/a |
| Affinity purified by Protein G |
| 0.01M PBS, 0.5%BSA, 0.02% Proclin300 |
| Store at 2-8°C |
| Target |
| 929.0 |
| P08571 |
| Monocyte Differentiation Antigen 14; CD14 antigen; CD14 molecule; Lipopolysaccharide receptor; LPSR; Monocyte differentiation antigen CD14; Myeloid cell specific leucine rich glycoprotein; CD14_HUMAN; Myeloid cell-specific leucine-rich glycoprotein. |
| The protein encoded by this gene is a surface antigen that is preferentially expressed on monocytes/macrophages. It cooperates with other proteins to mediate the innate immune response to bacterial lipopolysaccharide, and to viruses. This gene has been identified as a target candidate in the treatment of SARS-CoV-2-infected patients to potentially lessen or inhibit a severe inflammatory response. Alternative splicing results in multiple transcript variants encoding the same protein. [provided by RefSeq, Aug 2020] |
| Application Dilution |
| FCM |
10ul/10^6 cells in 100ul |